Epidemiological Characteristics of COVID-19 During Seven Consecutive Epidemiological Waves (2020-2022) in the North Bačka District, Serbia

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Nov 25

PMID 38005898

Authors

Jelena Banjac

Vladimir Vukovic

Tatjana Pustahija

Nebojsa Bohucki

Dragica Kovacevic Beric

Snezana Medic

Vladimir Petrovic

Mioljub Ristic

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic continues to pose a threat to global public health. The purpose of this research was to determine the epidemiological characteristics of COVID-19 in the North Bačka district while observing seven pandemic waves. The cross-sectional study was based on data from the COVID-19 surveillance database of the Institute for Public Health of Vojvodina during the period from March 2020 to December 2022. A total of 38,685 primary infections and 4067 reinfections caused by SARS-CoV-2 were notified. Pandemic waves caused by the Delta variant (cumulative incidence rate of 2482.37/100,000) and by the Omicron variant (cumulative incidence rate of 2994.45/100,000) emerged as significant focal points during the surveillance period. Over the course of three consecutive years (2020-2022), women were more affected (50.11%, 54.03%, and 55.68%, respectively). The highest incidence rates in age-specific categories were recorded in 2021 for the age group 40-49 (1345.32 per 10,000 inhabitants), while in 2022, they shifted towards the elderly population. Regarding vaccination status at the time of diagnosis, in 2021, around 15% of patients were vaccinated, while in 2022, the number increased to 37%. The most widely received vaccine was BBIBP-CorV (67.45%), followed by BNT162b2 (19.81%), Gam-COVID-Vac (9.31%), and ChAdOx1 nCoV-19 (3.42%) vaccine. The implementation of stringent public health measures and their mitigation, together with the emergence of new variants, influenced the dynamics of COVID-19 pandemic waves in the North Bačka district. Notably, throughout the study period, the working-age population was the most affected, along with females, with a mild clinical presentation dominating. Reinfections were most frequently recorded during the latter pandemic waves. Dealing with this pandemic has provided some valuable lessons for the development of future strategies in the case of a similar public health crisis.

References

Bajci M, Lendak D, Ristic M, Drljaca M, Brkic S, Turkulov V . COVID-19 Breakthrough Infections among Patients Aged ≥65 Years in Serbia: Morbidity and Mortality Overview. Vaccines (Basel). 2022; 10(11). PMC: 9695717. DOI: 10.3390/vaccines10111818. View

Ji W, Huh K, Kang M, Hong J, Bae G, Lee R . Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. J Korean Med Sci. 2020; 35(25):e237. PMC: 7324262. DOI: 10.3346/jkms.2020.35.e237. View

Sharma D, Notarte K, Fernandez R, Lippi G, Gromiha M, Henry B . In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing. J Med Virol. 2022; 95(1):e28241. PMC: 9874926. DOI: 10.1002/jmv.28241. View

Ristic M, Milosavljevic B, Vapa S, Markovic M, Petrovic V . Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLoS One. 2021; 16(7):e0254516. PMC: 8270141. DOI: 10.1371/journal.pone.0254516. View

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View

Musa S, Blazevic M, Kavazovic A, Durmisevic J, Skocibusic S . COVID-19 in the Federation of Bosnia and Herzegovina: Strengthening the public health surveillance using a web-based system to inform public health response, March 2020 - March 2022. Biomol Biomed. 2023; 23(4):718-725. PMC: 10351090. DOI: 10.17305/bb.2022.8050. View

Hu B, Guo H, Zhou P, Shi Z . Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020; 19(3):141-154. PMC: 7537588. DOI: 10.1038/s41579-020-00459-7. View

Rahman M, Thill J . Associations between COVID-19 Pandemic, Lockdown Measures and Human Mobility: Longitudinal Evidence from 86 Countries. Int J Environ Res Public Health. 2022; 19(12). PMC: 9223807. DOI: 10.3390/ijerph19127317. View

Perez-Alos L, Almagro Armenteros J, Madsen J, Hansen C, Jarlhelt I, Hamm S . Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022; 13(1):1614. PMC: 8960902. DOI: 10.1038/s41467-022-29225-4. View

10.

Notarte K, Catahay J, Peligro P, Velasco J, Ver A, Guerrero J . Humoral Response in Hemodialysis Patients Post-SARS-CoV-2 mRNA Vaccination: A Systematic Review of Literature. Vaccines (Basel). 2023; 11(4). PMC: 10142871. DOI: 10.3390/vaccines11040724. View

11.

Wu C, Qian Y . The gender peak effect: Women are most vulnerable to infections during COVID-19 peaks. Front Public Health. 2022; 10:937179. PMC: 9395988. DOI: 10.3389/fpubh.2022.937179. View

12.

Petrovic V, Vukovic V, Patic A, Markovic M, Ristic M . Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. PLoS One. 2022; 17(2):e0263468. PMC: 8809561. DOI: 10.1371/journal.pone.0263468. View

13.

Pustahija T, Ristic M, Medic S, Vukovic V, Strbac M, Rajcevic S . Epidemiological characteristics of COVID-19 travel-associated cases in Vojvodina, Serbia, during 2020. PLoS One. 2021; 16(12):e0261840. PMC: 8699980. DOI: 10.1371/journal.pone.0261840. View

14.

Siddiqui S, Alhamdi H, Alghamdi H . Recent Chronology of COVID-19 Pandemic. Front Public Health. 2022; 10:778037. PMC: 9114873. DOI: 10.3389/fpubh.2022.778037. View

15.

Honardoost M, Janani L, Aghili R, Emami Z, Khamseh M . The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis. Cerebrovasc Dis. 2021; 50(2):132-140. PMC: 7900456. DOI: 10.1159/000513288. View

16.

Young M, Crook H, Scott J, Edison P . Covid-19: virology, variants, and vaccines. BMJ Med. 2023; 1(1):e000040. PMC: 9951271. DOI: 10.1136/bmjmed-2021-000040. View

17.

Petrovic V, Vukovic V, Markovic M, Ristic M . Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia. Vaccines (Basel). 2022; 10(3). PMC: 8954033. DOI: 10.3390/vaccines10030389. View

18.

Lin L, Liu Y, Tang X, He D . The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. Front Public Health. 2021; 9:775224. PMC: 8669511. DOI: 10.3389/fpubh.2021.775224. View

19.

Liu Y, Yu Q, Wen H, Shi F, Wang F, Zhao Y . What matters: non-pharmaceutical interventions for COVID-19 in Europe. Antimicrob Resist Infect Control. 2022; 11(1):3. PMC: 8743060. DOI: 10.1186/s13756-021-01039-x. View

20.

Ao D, Lan T, He X, Liu J, Chen L, Baptista-Hon D . SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm (2020). 2022; 3(1):e126. PMC: 8925644. DOI: 10.1002/mco2.126. View